Steven John Green
Directeur/Membre du Conseil chez Biogen Idec Ltd.
Profil
Steven John Green is currently a Director at Biogen Idec Ltd., Convergence Pharmaceuticals Ltd., Amicus Therapeutics International Holding Ltd., Silver Acquisition Co. Ltd., Convergence Pharmaceuticals Holdings Ltd., and Old Convergence Pharmaceuticals Ltd.
He was previously a Director at Nightstar Therapeutics Ltd.
from 2019 to 2020.
Postes actifs de Steven John Green
| Sociétés | Poste | Début |
|---|---|---|
Biogen Idec Ltd.
 Biogen Idec Ltd. BiotechnologyHealth Technology Biogen Idec Ltd. develops therapies for neurodegenerative, haematologic, and autoimmune disorders. The firm develops treatment for Alzheimer’s Disease, spinal muscular atrophy, lupus, and amyotrophic lateral sclerosis (ALS), amongst others. The company was founded on 2003 and is headquartered in Maidenhead, the United Kingdom. | Directeur/Membre du Conseil | 27/07/2011 |
Convergence Pharmaceuticals Holdings Ltd.
 Convergence Pharmaceuticals Holdings Ltd. Financial ConglomeratesFinance Part of Biogen, Inc., Convergence Pharmaceuticals Holdings Ltd. functions as an investment holding British company. The company is based in Maidenhead, UK. | Directeur/Membre du Conseil | - |
Silver Acquisition Co. Ltd.
 Silver Acquisition Co. Ltd. BiotechnologyHealth Technology Founded in 2014, Silver Acquisition Co. Ltd. is a biotechnology research and British experimental development company. Part of Biogen, Inc., the company is based in Maidenhead, UK. The company's focus is on developing new biotechnology products through research and experimentation. | Directeur/Membre du Conseil | 19/12/2014 |
Convergence Pharmaceuticals Ltd.
 Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Directeur/Membre du Conseil | 06/01/2015 |
Old Convergence Pharmaceuticals Ltd.
 Old Convergence Pharmaceuticals Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2010, Old Convergence Pharmaceuticals Ltd. is a subsidiary of Biogen, Inc. that develops analgesics for the treatment of chronic pain. The company is based in Maidenhead, UK. | Directeur/Membre du Conseil | 12/04/2018 |
Amicus Therapeutics International Holding Ltd.
 Amicus Therapeutics International Holding Ltd. Financial ConglomeratesFinance Founded in 2016, Amicus Therapeutics International Holding Ltd. is a British company that functions as an investment holding company. Part of Amicus Therapeutics, Inc., the company is based in Marlow, UK. | Directeur/Membre du Conseil | 01/06/2020 |
Anciens postes connus de Steven John Green
| Sociétés | Poste | Fin |
|---|---|---|
| NIGHTSTAR THERAPEUTICS PLC | Directeur/Membre du Conseil | 24/04/2020 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Biogen Idec Ltd.
Biogen Idec Ltd. BiotechnologyHealth Technology Biogen Idec Ltd. develops therapies for neurodegenerative, haematologic, and autoimmune disorders. The firm develops treatment for Alzheimer’s Disease, spinal muscular atrophy, lupus, and amyotrophic lateral sclerosis (ALS), amongst others. The company was founded on 2003 and is headquartered in Maidenhead, the United Kingdom. | Health Technology |
Convergence Pharmaceuticals Holdings Ltd.
Convergence Pharmaceuticals Holdings Ltd. Financial ConglomeratesFinance Part of Biogen, Inc., Convergence Pharmaceuticals Holdings Ltd. functions as an investment holding British company. The company is based in Maidenhead, UK. | Finance |
Silver Acquisition Co. Ltd.
Silver Acquisition Co. Ltd. BiotechnologyHealth Technology Founded in 2014, Silver Acquisition Co. Ltd. is a biotechnology research and British experimental development company. Part of Biogen, Inc., the company is based in Maidenhead, UK. The company's focus is on developing new biotechnology products through research and experimentation. | Health Technology |
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Old Convergence Pharmaceuticals Ltd.
Old Convergence Pharmaceuticals Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2010, Old Convergence Pharmaceuticals Ltd. is a subsidiary of Biogen, Inc. that develops analgesics for the treatment of chronic pain. The company is based in Maidenhead, UK. | Commercial Services |
Nightstar Therapeutics Ltd.
 Nightstar Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nightstar Therapeutics Ltd. is a clinical-stage gene therapy. It engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. The company was founded by Robert MacLaren, Miguel Seabra and Matthew During in 2014 and is headquartered in London, the United Kingdom. | Health Technology |
Amicus Therapeutics International Holding Ltd.
Amicus Therapeutics International Holding Ltd. Financial ConglomeratesFinance Founded in 2016, Amicus Therapeutics International Holding Ltd. is a British company that functions as an investment holding company. Part of Amicus Therapeutics, Inc., the company is based in Marlow, UK. | Finance |
